Skip to main content

Day: May 4, 2022

Solvay first quarter 2022 results

May 4, 2022 at 7 a.m. CEST Solvay first quarter 2022 results 26% sales growth driven by strong pricing leads to record EBITDA HighlightsNet Sales in the first quarter of 2022 were over €3 billion, a new quarterly record, up +26.1% organically versus Q1 2021, with double-digit sales growth in every business and all regions driven by successful price actions (+20% or €475 million) and volume growth (+6% or €157 million). Structural cost savings of €22 million were achieved in Q1 2022, totaling €410 million since 2020, and on track to achieve our €500 million mid-term target ahead of plan. Record underlying EBITDA in Q1 2022 of €712 million was +20% higher on an organic basis. All three segments delivered double-digit EBITDA growth driven by price and volumes. Price gains in the quarter more than offset €369 million of inflationary cost...

Continue reading

8/2022・Trifork Group – Report of the quarter ending 31 March 2022

Company announcement no. 8 / 2022   Schindellegi, Switzerland – 4 May 2022   Trifork Group reports continued strong organic revenue growth in Q1 2022 and confirms full year guidance. First quarter of 2022Revenue of Trifork Group (“Trifork”) in the first quarter of 2022 was EURm 45.8, an increase of 16.3% compared to the same period in 2021. Revenue grew organically by 17.8% (adjusted for deconsolidation of Dawn Health) compared to the first quarter of 2021 and was driven by high organic growth from Fintech and Cyber Protection in the Build and Run sub-segments. Trifork segment adjusted EBITDA in Q1 2022 increased by 5.1% to EURm 8.1 from EURm 7.7 in Q1 2021, corresponding to an adjusted EBITDA margin of 17.6%. The Inspire sub-segment now has reached a cumulative 31.8 million views on the GOTO YouTube channel since inception. In...

Continue reading

Equinor first quarter 2022

Equinor (OSE: EQNR, NYSE: EQNR) reports adjusted earnings of USD 18.0 billion and USD 5.18 billion after tax in the first quarter of 2022. IFRS net operating income was USD 18.4 billion and the IFRS net income was USD 4.71 billion. The first quarter of 2022 was characterised by:The invasion of Ukraine impacting already tight energy markets, increasing commodity prices and volatility. Strong operational performance and increased production of gas to Europe to support energy security. Very strong adjusted earnings and free cash flow* of USD 12.7 billion. Announced process for exiting Russia leading to an impairment of USD 1.08 billion. Continued progress on all strategic priorities with continued cost focus and capital discipline. Cash dividend of USD 0.20 per share, continued extraordinary cash dividend of USD 0.20 per share and second...

Continue reading

Blueberries Medical Reports 2021 Financial Results

TORONTO, May 03, 2022 (GLOBE NEWSWIRE) — Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA) the Canadian parent of Blueberries S.A.S. (“BBSAS”), the premier Latin American licensed cultivator and producer of medicinal cannabis and medicinal-grade cannabis extracts, (together the “Company” or “Blueberries“), is pleased to report its financial results for the year ended December 31, 2021. Blueberries has filed today its audited consolidated financial statements and related management’s discussion and analysis, both of which are available on Blueberries’ profile at www.sedar.com. All financial information in this press release is reported in Canadian dollars, unless otherwise indicated. “2021 was a year of tremendous changes to the Cannabis Industry, and Blueberries was definitely part of it,” said...

Continue reading

Positive final results in stroke

World-first stroke study CUV801 evaluating afamelanotideFigure 1 – CUV801 MRI-FLAIR results Individual patient data of brain scans (MRI-FLAIR) showing a reduction of the affected area in five of the six patients treated in CUV801.Figure 2 – CUV801 NIHSS results Individual NIHSS scores in five of six patients treated in the CUV801 study showed improvement in neurological functions. Two patients were symptom free at day 42. ASX: XETRA-DAX:  Level 1 ADR: CUV UR9 CLVLY EXECUTIVE SUMMARYafamelanotide evaluated as safe in mild to moderate arterial ischaemic stroke (NIHSS 1–15, n=6) NIHSS1 scores improved in five patients brain scans (MRI-FLAIR2) in all patients show reduction of affected tissue strong functional recovery in all five surviving patientsMELBOURNE, Australia, May 03, 2022 (GLOBE NEWSWIRE) — CLINUVEL...

Continue reading

Black Diamond Group Announces Approval of All Resolutions at 2022 Annual Meeting

CALGARY, Alberta, May 03, 2022 (GLOBE NEWSWIRE) — Black Diamond Group Limited (“Black Diamond” or the “Company”) (TSX: BDI) announced the voting results from its annual meeting of shareholders held on May 3, 2022. A total of 33,715,077 common shares, representing approximately 56.2% of Black Diamond’s issued and outstanding common shares, were represented in person or by proxy at the meeting. The following nominees were elected as directors of Black Diamond for the ensuing year, with the specific voting results being as follows:Nominee Votes For % For Votes Withheld % WithheldTrevor Haynes 33,097,127 99.88 40,646 0.12Brian Hedges 33,096,377 99.88 41,396 0.12Robert J. Herdman 33,095,427 99.87 42,346 0.13Barbara J. Kelley 32,089,587 96.84 1,048,186 3.16Edward H. Kernaghan 33,067,126 99.79 70,647 0.21Leilani Latimer 33,004,940 99.60 132,833 0.40Steven...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.